Wockhardt Secures US FDA Approval for ZAYNICH: A Milestone for Indian Pharma
Decision brief
Answer first · skim in under a minute
Wockhardt has achieved a historic milestone with the FDA approval of ZAYNICH, a novel antibiotic. This development signals potential growth opportunities in the pharmaceutical sector.
Wockhardt’s ZAYNICH (cefepime and zidebactam) received U.S. FDA approval for adults with complicated urinary tract infections, including pyelonephritis. The decision rests on Phase 3 ENHANCE-1 results and corrects older drafts that wrongly dated approval to 2023.
Contents9 sections
Key Takeaways
- FDA approved ZAYNICH for adult cUTI including pyelonephritis caused by susceptible Gram-negative pathogens; DailyMed shows NDA 220787 and marketing start May 29, 2026.
- ENHANCE-1 composite cure/micro response: 89.0% ZAYNICH vs 68.4% meropenem (difference 20.6%; 95% CI 12.3–29.5).
- Prior FDA designations: Qualified Infectious Disease Product (QIDP) and Fast Track, per Wockhardt.
- India DCGI approval: May 27, 2026; EMA MAA submitted, per company statements.
What exactly did FDA approve for ZAYNICH?
ZAYNICH combines cefepime, a cephalosporin antibacterial, with zidebactam, a non–β-lactam β-lactamase inhibitor/enhancer. The U.S. indication is intravenous treatment of adults with complicated UTI, including pyelonephritis, due to susceptible Gram-negative pathogens. DailyMed lists initial U.S. approval as 2026.
Label source: DailyMed — ZAYNICH (cefepime and zidebactam).
What did ENHANCE-1 show?
Wockhardt said FDA approval was based in part on ENHANCE-1, a Phase 3 randomized, double-blind, multicenter study versus meropenem in hospitalized adults with cUTI or acute pyelonephritis. The study enrolled 530 patients across 64 sites in the U.S., Europe, LATAM, China, and India.
- Primary composite clinical cure + microbiological response: 89.0% vs 68.4%
- Treatment difference: 20.6% (95% CI 12.3–29.5)
- Company characterization: generally well tolerated in Phase 3
Wire: PR Newswire — Wockhardt ZAYNICH FDA approval.
Why does the approval matter for Indian innovative pharma?
Company leadership framed ZAYNICH as a landmark for an India-origin novel antibiotic reaching the U.S. market. That industrial narrative is newsworthy, but BD models should separate “first India-developed NCE antibiotic” messaging from labeled clinical scope: the U.S. approval described here is for cUTI/pyelonephritis, not a broad blanket for HABP/VABP or cIAI unless and until those indications are approved.
Wockhardt also said ZAYNICH previously received QIDP and Fast Track designations from FDA.
What are the next commercial and regulatory checkpoints?
Watch U.S. launch timing, hospital formulary uptake against carbapenems, and stewardship restrictions for novel Gram-negative agents. Outside the U.S., track India’s commercial rollout after the May 27, 2026 DCGI approval and EMA review of the submitted MAA. Expanded-access history in multiple countries does not substitute for local marketing authorization.
What remains unproven?
This rewrite deletes the incorrect October 15, 2023 FDA-approval date that appeared in earlier drafts. Public primaries cited here do not establish U.S. peak sales, a $9 billion market capture claim as a company fact for diligence, or approval for pneumonia or intra-abdominal infection indications. Do not invent resistance-rate superiority beyond the ENHANCE-1 composite endpoint.
Related NovaPharma coverage
- FDA Approves Bact-Away for Resistant Infections
- FDA Approves VitaCorp Antibiotic
- FDA Approves OTC Rextovy
Frequently Asked Questions
What is ZAYNICH and what did FDA approve it for?
ZAYNICH is cefepime and zidebactam for injection. FDA approved it for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. DailyMed lists initial U.S. approval in 2026 and NDA 220787 with marketing start May 29, 2026.
What efficacy did ENHANCE-1 show for ZAYNICH?
In Phase 3 ENHANCE-1, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem, a treatment difference of 20.6% (95% CI 12.3–29.5), in hospitalized adults with cUTI or acute pyelonephritis (n=530 across 64 sites).
When was ZAYNICH approved in the US and India?
Wockhardt announced U.S. FDA approval around May 30–June 1, 2026. The company also said India’s DCGI approved ZAYNICH on May 27, 2026, and that an EMA marketing authorization application has been submitted.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for ZAYNICH.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
